Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated April 13, 2026, reports on positive clinical data from the global Phase 1 BEHOLD-1 trial for mocertatug rezetecan (Mo-Rez), a B7-H4-targeted antibody-drug conjugate (ADC). The announcement focuses on gynaecological cancers, specifically platinum-resistant ovarian cancer (PROC) and recurrent or advanced endometrial cancer (EC).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a clinical update and does not contain financial statements or quarterly results.
Material Changes and Clinical Results
The primary material change is the advancement of the Mo-Rez development program based on interim efficacy and safety data:
- Efficacy in PROC: Confirmed objective response rate (cORR) of 62% (5.8 mg/kg, n=21/34).
- Efficacy in EC: Confirmed objective response rate (cORR) of 67% (4.8 mg/kg, n=8/12).
- Safety Profile: Treatment-related adverse events (TRAEs) led to discontinuation in 0% of PROC patients and 4% of EC patients. The most common TRAE was nausea (82% in PROC; 75% in EC). Grade 3+ TRAEs occurred in 64% (PROC) and 54% (EC), predominantly haematologic. Interstitial lung disease/pneumonitis rates were low (3%) and mild to moderate.
- Development Milestone: GSK announced the initiation of five pivotal Phase III trials in 2026, starting with BEHOLD-Ovarian01 and BEHOLD-Endometrial01.
Guidance, Outlook, and Risks
Outlook and Management Commentary: Management views the data as compelling evidence supporting the acceleration of development. The recommended dose for the first Phase III trials is set at 5.8 mg/kg. The company aims to expand its oncology portfolio into lung and gastrointestinal cancers alongside its current focus on blood and women's cancers.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements. Actual results may differ materially due to risks described in GSK's 2025 Annual Report on Form 20-F, including clinical trial outcomes, regulatory approvals, and commercialization challenges.
Investor Verification Checklist
- Verify the enrollment numbers and statistical significance of the cORR in the full BEHOLD-1 dataset (n=224 total).
- Confirm the timeline and specific inclusion criteria for the five announced Phase III trials (BEHOLD-Ovarian01/02/03 and BEHOLD-Endometrial01/02).
- Review the long-term safety data, specifically the duration of response and incidence of late-onset toxicities as the trial continues.
- Assess the commercial potential of Mo-Rez given the acquisition of rights from Hansoh Pharma (excluding mainland China, Hong Kong, Macau, and Taiwan).
- Monitor the presentation of these data at the Society of Gynecologic Oncology (SGO) Annual Meeting for peer review and additional context.